Optimising regulatory T cell depletion in combination with chemotherapy for enhanced anti-tumour immunity

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/572593

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The drug cyclophosphamide helps the immune system attack cancer by decreasing the number of immune cells that suppress an immune response to cancer ('Regulatory T cells'). This project combines standard chemotherapy with the drug cyclophosphamide in people with mesothelioma and lung cancer. The aim of the project is to find the dose of cyclophosphamide that maximally decreases Regulatory T cells in each patient, and determine the effect of this on anti-tumour immunity and response to treatment.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $264,816.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell immunity | asbestos | cancer chemotherapy | chemotherapy | clinical trial | lung cancer | malignant mesothelioma | tumour immunotherapy

Related Links